What it Takes to Scale Past Scrappy

The thing that Series A celebrates, doing everything yourself, is the same thing that prevents Series B from arriving on schedule.

I've had some version of this conversation four times in the past month. A founder, eighteen months post-close, working harder than they were pre-close. Revenue moving, but not as fast as the model assumed. A team that's capable but not quite cohesive. A board that's starting to ask questions with a different tone.

And a founder who is still, in some fundamental way, running the company the way they did at fifteen people. Not out of habit. Out of genuine uncertainty about what delegating authority actually looks like, and fear of what happens when they test it.

This month I want to write about the structural shifts that separate the founders who navigate Series A well from the ones who find themselves, two years later, running a company that's growing but not thriving.

SHIFT 1: AUTHORITY FROM FOUNDER TO TEAM

The most consistent pattern I see in companies that are underperforming their model: the decision rights haven't been transferred. The founder is still the decision node for things that their team should own, not because the team isn't capable, but because the system for making decisions hasn't been rebuilt to accommodate the new size.

At fifteen people, founder-as-decision-node works. Everyone has context. The founder has full visibility. Decisions are fast.

At fifty people, it breaks. The founder no longer has full visibility. The team has lost the habit of escalating decisions because the queue is too long. Decisions slow down. The team stops bringing problems up because they've learned that problems don't move. The culture of initiative disappears, not dramatically, but steadily.

The fix is structural: a decision rights framework that defines, for every recurring category of decision, who owns it, what information they need to make it, and what the escalation pathway looks like. Not a policy document. A working tool that the team uses and the founder reinforces by not overriding it.

The founders who get this right do it before it's necessary, at twenty-five people, when it still feels premature. That's the move.

SHIFT 2: SALES FROM RELATIONSHIP TO PROCESS

Founder-led sales works brilliantly up to a point. The founder can close anyone. They have full product knowledge, full conviction, full flexibility. They can make the call in the room that no sales rep would be authorised to make.

And then they hit the ceiling. The company needs ten enterprise contracts closed this quarter. The founder can personally close two. The gap, the eight contracts that don't get closed, is the Series B problem.

The transition from founder-led to team-led sales requires building the commercial process before you hire the commercial team. Not the other way around. The failure mode is hiring experienced sales people into a process-free environment and expecting them to build process while also hitting targets. They won't. The best ones will leave. The ones who stay will have adapted to the chaos and will be hard to manage when you eventually install the process.

Build the process first. Hire into it second. In HealthTech specifically: the NHS procurement cycle, the evidence requirements, the multi-stakeholder buying committee, these need to be documented as a sales process, not navigated from scratch on every deal.

SHIFT 3: NARRATIVE FROM TECHNICAL TO COMMERCIAL

The narrative that earned the Series A is not the narrative that earns the Series B. Series A investors backed a founder and a vision. Series B investors are backing a commercial trajectory and a path to exits.

The shift from technical to commercial narrative is one that many founders find genuinely uncomfortable, because it requires talking about the company in terms of revenue model, customer acquisition economics, and market size in ways that feel reductive when you know how complex the clinical evidence is.

But the commercial narrative is not a simplification of the technical reality. It's a translation of it into the language of the next decision-maker. Getting that translation right, specific enough to be credible, clear enough to be usable, is the work.

What I'm Watching 

One HealthTech market observation: the shift from innovation narrative to evidence narrative in UK procurement is now visible in NHS contract documentation. NHAP pilot trusts are requiring outcome evidence at the point of commercial pilot - not as a nice-to-have, but as a contractual requirement. This is a structural shift in how HealthTech companies will need to build their commercial pipeline from this year forward.

The companies that built evidence collection into their product from the start are finding it easier. The ones that built for adoption metrics, usage rates, clinician satisfaction, implementation speed, are discovering that those metrics don't satisfy the new commissioning requirement. The conversion from pilot to contract is failing at a higher rate than it should because the evidence doesn't match what NHS England is now asking for.

Design your evidence strategy before you design your product. Or, if it's too late for that: retrofit it now.

If any of this resonates, particularly the commercial narrative piece, I'd be glad to talk through what it looks like in your specific company. No commitment, no pitch. Just a conversation.

DM me, or reply to this email.

Two newsletter editions a month. Forward to a founder who needs it.

— Sara